FEB 24, 2016 5:00 AM PST

How Personalised Healthcare is transforming drug development

Speakers
  • VP and Head of Personalised Healthcare and Biomarkers, AstraZeneca
    Biography
      Ruth March, VP and Head of Personalised Healthcare and Biomarkers, leads AstraZeneca's function of world class diagnostic and biomarker science experts, delivering companion diagnostic tests to target AZ drugs to the right patients across each therapy area and all phases of development. She has driven adoption of Personalised Healthcare approaches by 70% of AstraZeneca's pipeline, partnering with a strategic network of diagnostic companies to ensure delivery to global clinical trials and marketed products.

      Ruth spent ten years in immunology and genetics research at the Universities of London and Oxford. She has over 40 publications and patents in the field of pharmacogenomics and Personalised Healthcare and serves as an expert evaluator for the European Commission.

    Abstract:

    Personalised Healthcare is essential to AstraZeneca’s approach to drug development and is adopted by more than 80% of drug products in clinical development. Selection of the right patient population using companion diagnostics is integral to the way in which AstraZeneca focuses on quality and innovation. We will discuss examples where Personalised Healthcare has transformed the delivery of new therapies to patients. We will examine how emerging diagnostic science has the potential to improve patient outcomes; including circulating tumour DNA, next generation sequencing and expanding the benefits of Personalised Healthcare across all therapy areas. Finally we will consider the role of partnerships to delivering Personalised Healthcare into clinical practice. We believe that Personalised Healthcare is the future of drug development; it epitomizes what science can do.
     
    Learning objectives:

    • Describe how Personalised Healthcare been used to help transform AstraZeneca’s approach to drug development
    • Understand examples of the use of Personalised Healthcare to develop novel therapies
    • Evaluate the role of emerging diagnostic science to deliver benefit to patients

    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    Loading Comments...
    Show Resources